Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $3.1 million.

  • Stoke Therapeutics' Cash from Financing Activities fell 6176.0% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 9592.66%. This contributed to the annual value of $131.1 million for FY2024, which is 14731.45% up from last year.
  • Stoke Therapeutics' Cash from Financing Activities amounted to $3.1 million in Q3 2025, which was down 6176.0% from $554000.0 recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Cash from Financing Activities ranged from a high of $120.6 million in Q2 2024 and a low of $43000.0 during Q4 2022
  • Moreover, its 4-year median value for Cash from Financing Activities was $1.7 million (2024), whereas its average is $15.7 million.
  • Per our database at Business Quant, Stoke Therapeutics' Cash from Financing Activities surged by 25125416.67% in 2024 and then crashed by 9954.08% in 2025.
  • Stoke Therapeutics' Cash from Financing Activities (Quarter) stood at $43000.0 in 2022, then skyrocketed by 16976.74% to $7.3 million in 2023, then plummeted by 92.26% to $568000.0 in 2024, then skyrocketed by 449.3% to $3.1 million in 2025.
  • Its Cash from Financing Activities stands at $3.1 million for Q3 2025, versus $554000.0 for Q2 2025 and $1.4 million for Q1 2025.